Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia

Rodríguez-Tudela, Juan L., Almirante, Benito, Rodríguez-Pardo, Dolors, Laguna, Fernando, Donnelly, J. Peter, Mouton, Johan W., Pahissa, Albert, Cuenca-Estrella, Manuel·2007·Antimicrobial Agents and Chemotherapy
DOI 10.1128/aac.00296-07

Cited by (137)

Items 101–137 of 137

  1. Candida ve Kandidoz: Epidemiyoloji, Tanı, Tedavi, Antifungal İlaç Direnci ve Konağın Genetik Yatkınlığında Güncel Durum
    Seyedmojtaba Seyedmousavi, Macit İlkit, Murat Durdu, Çağrı Ergin, Süleyha Hilmioğlu Polat, Willem J. G. Melchers, Paul E. Verweij · 2015 · Türk Mikrobiyoloji Cemiyeti Dergisi
  2. Usefulness of Yeast Cell Counting and Lack of Clinical Correlation of the Antifungal Susceptibility Testing Results in Management of Aids-associated Cryptococcal Meningitis
    Oscar José Chagas, Renata Buccheri, Márcia de Souza Carvalho Melhem, Walderez Szeszs, Marilena dos Anjos Martins, Lidiane de Oliveira, Rosa Maria Nascimento Marcusso, Daniel Wagner de Castro Lima Santos · 2020 · Current Fungal Infection Reports
  3. Fluconazole step-down therapy versus echinocandins for the treatment of Candida glabrata invasive candidiasis with candidaemia
    Madeline Droney, Erica E. Reed, Sajed Sarwar, Kelci E. Coe, Nikki N. Tran · 2025 · Journal of Antimicrobial Chemotherapy
  4. Opportunistic and systemic fungi
    Thomas G. Mitchell, Paul E. Verweij, Andy I. M. Hoepelman · 2010 · Elsevier eBooks
  5. Antifungal Pharmacokinetics and Pharmacodynamics
    David R. Andes, Alex J. Lepak · 2010 · Springer eBooks
  6. Susceptibility Testing of Candida auris Isolates
    Elizabeth M. Johnson, Andrew M. Borman · 2022 · Methods in molecular biology
  7. [Not Available].
    Julie Arnould, R. Le Floch · 2015 · PubMed
  8. Can Fluconazole Be Used to Treat Non-Resistant Candida ( Candidozyma ) auris Infections? Preclinical Pharmacokinetic/Pharmacodynamic Data From a Galleria mellonella Infection Model
    Vasiliki Kroustali, Spyros Pournaras, Joseph Meletiadis · 2026 · The Journal of Infectious Diseases
  9. Moulds: diagnosis and treatment
    Paul E. Verweij, Johan A. Maertens · 2009 · Journal of Antimicrobial Chemotherapy
  10. Pharmacodynamics of antifungal drugs: A strategy to optimize efficacy
    Alex J. Lepak, David R. Andes · 2008 · Current Fungal Infection Reports
  11. Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated Candidiasis
    Javier Mauricio González, Carlos Andrés Rodríguez, Andrés Felipe Zuluaga, María Agudelo, Ómar Vesga · 2015 · PLoS ONE
  12. Population Pharmacokinetic Analysis and Dosing Optimization of Prophylactic Fluconazole in Japanese Patients with Hematological Malignancy
    Yasutaka Sakamoto, Hikaru Isono, Yuki Enoki, Kazuaki Taguchi, Takuya Miyazaki, Hiroyoshi Kunimoto, Hirofumi Koike, Maki Hagihara, Kenji Matsumoto, Hideaki Nakajima et al. · 2021 · Journal of Fungi
  13. Clinical application of antifungal pharmacodynamics
    Jason C Gallagher · 2009 · Current Fungal Infection Reports
  14. Practical Pharmacokinetics and Pharmacodynamics
    Anthony Thomas Gerlach, Lina Saliba · 2016 · Springer eBooks
  15. Antifungal Pharmacokinetics and Pharmacodynamics
    William W. Hope, David R. Andes · 2016 · Methods in pharmacology and toxicology
  16. Azoles
    Laura Cottom, Arthur S. McPhee · 2021 · Elsevier eBooks
  17. Susceptibility Test Methods: Yeasts and Filamentous Fungi
    Elizabeth M. Johnson, Maiken Cavling Arendrup · 2023 · ClinMicroNow
  18. Susceptibility Test Methods: Yeasts and Filamentous Fungi
    Elizabeth M. Johnson, Maiken Cavling Arendrup · 2023 · ClinMicroNow
  19. Using Antifungal Pharmacodynamics to Improve Patient Outcomes
    Nathan P. Wiederhold · 2010 · Current Fungal Infection Reports
  20. Mechanisms of Multidrug Resistance in Fungal Pathogens
    Sélène Ferrari, Dominique Sanglard · 2009 · Springer eBooks
  21. Estudo retrospectivo de dez anos de candidemia em hospital terciário de Campo Grande-MS, Brasil
    Lucas Xavier Bonfietti, Márcia de Souza Carvalho Melhem · 2011 · BEPA Boletim Epidemiológico Paulista
  22. Caracterização e avaliação do perfil de suscetibilidade a antifúngicos dos agentes de candidemia em hospital público de referência da Baixada Santista, Brasil
    Fabiana Cortez Pimentel · 2012
  23. Niveau de preuve du suivi thérapeutique pharmacologique du fluconazole
    Nicolas Venisse, Chantal Barin‐Le Guellec · 2011 · Therapies
  24. Pharmacodynamics of anti-infective agents
    Johan Willem Mouton · 2010 · Elsevier eBooks
  25. Usefulness of Antifungal Reference In Vitro Susceptibility Tests as a Guide in Therapeutic Management
    Ana Espinel‐Ingroff, Maurizio Sanguinetti, Brunella Posteraro · 2019 · Current Fungal Infection Reports
  26. Antimicrobial Resistance
    Prakash Singh Bisen, Ruchika Raghuvanshi · 2013
  27. Applied Antifungal Pharmacometrics: Fluconazole and Echinocandins in the Treatment of Candidemia and Invasive Candidiasis
    Cornelius Joseph Clancy · 2014 · AAPS advances in the pharmaceutical sciences series
  28. Current fluconazole dosing regimens in critically ill adults result in under-exposure during early therapy
    Indy Sandaradura, Deborah J. E. Marriott, Richard Osborne Day, Ross L. G. Norris, Edna Pang, SOPHIE LENA STOCKER, Stephanie Reuter Lange · 2020
  29. Abordagem PK/PD para avaliar a efetividade do fluconazol nas infecções fúngicas causadas por Candida spp. em pacientes queimados de UTI
    Victor Kaneko Matsuno · 2021
  30. Abordagem farmacocinética e farmacodinâmica no monitoramento terapêutico de antibióticos e antifúngicos em pacientes pediátricos pós-transplante hepático
    Ronaldo Morales · 2023
  31. Therapeutic drug monitoring of selected antifungal agents
    Matthew D. Krasowski · 2024 · Elsevier eBooks
  32. Population pharmacokinetics of fluconazole for prevention or treatment of invasive candidiasis in Chinese young infants
    Honghong Wang, Dandan Li, Yongjiang Jiang, Jing Liang, Qiaoai Yu, Linghong Kuang, Yuling Huang, Dongjie Qin, Ping Li, Jing He et al. · 2024 · Naunyn-Schmiedeberg s Archives of Pharmacology
  33. Additional file 2 of Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study
    Mahipal Sinnollareddy, Jason Alexander Roberts, Jeffrey Lipman, Akova, Murat, Bassetti, Matteo, De Waele, Jan J, Kaukonen, Kirsi-Maija, Despoina Koulenti, Martin, Claude, Philippe Montravers et al. · 2021 · Figshare
  34. Additional file 1 of Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study
    Mahipal Sinnollareddy, Jason Alexander Roberts, Jeffrey Lipman, Akova, Murat, Bassetti, Matteo, De Waele, Jan J, Kaukonen, Kirsi-Maija, Despoina Koulenti, Martin, Claude, Philippe Montravers et al. · 2021 · Figshare
  35. A Pharmacokinetic Analysis of Intravenous Fluconazole in Adult Patients Undergoing Mechanical Circulatory Support Device Implantation
    Kelly A. Cairns, María Patricia Hernández-Mitre, Trisha Nicole Peel, Iain J. Abbott, David M. Kaye, Silvana Marasco, David Daly, VICTOR T. WARNER, Anna Coldham, Jeffrey D. Pope et al. · 2025 · Clinical Pharmacokinetics
  36. Interactions hôte-candida au cours des péritonites fongiques graves de réanimation
    Emmanuel Novy · 2024 · theses.fr (ABES)
  37. Evaluation of an early step-down (≤5 days) strategy from echinocandins to azole therapy for the treatment of invasive candidiasis
    Marta Albanell‐Fernández, Montserrat Tuset, A Vergara, M Villanueva, Melisa Barrantes-González, Marta Bodro, Àlex Soriano, Sabina Herrera · 2026 · Journal of Antimicrobial Chemotherapy